Form 8-K - Current report:
SEC Accession No. 0001193125-21-304056
Filing Date
2021-10-21
Accepted
2021-10-21 16:31:59
Documents
13
Period of Report
2021-10-19
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d343945d8k.htm   iXBRL 8-K 26533
2 EX-99.1 d343945dex991.htm EX-99.1 17367
  Complete submission text file 0001193125-21-304056.txt   171682

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dvax-20211019.xsd EX-101.SCH 2890
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dvax-20211019_lab.xml EX-101.LAB 18140
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dvax-20211019_pre.xml EX-101.PRE 11407
6 EXTRACTED XBRL INSTANCE DOCUMENT d343945d8k_htm.xml XML 3400
Mailing Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34207 | Film No.: 211337345
SIC: 2834 Pharmaceutical Preparations